Medik8 Expands into Sephora

Medik8, the British premium clinical skincare brand known for its research-first approach to skin health, announced a major expansion with Sephora across North America. 

The partnership marks a significant milestone in Medik8’s North American growth strategy, expanding access to its clinically proven, science-led skincare for Sephora’s increasingly ingredient-savvy clients.

Medik8 also aims to establish Crystal Retinal as its leading franchise in the U.S., mirroring its success across the brand’s other global markets. 

Simon Coble, Chief Executive Officer of Medik8, commented:

“American consumers are more informed than ever about skincare ingredients and increasingly expect clinically proven performance, not marketing promises. That shift aligns directly with how Medik8 has built the brand from day one. Sephora’s understanding of its skincare client and unmatched scale make it the ideal partner to bring our research-led approach to a broader audience. Our ambition is to establish Medik8 as one of Sephora’s top 10 skincare brands over the next three to five years.”

Crystal Retinal features Medik8’s signature CSA Philosophy, Vitamin C and Sunscreen by day and Vitamin A (also known as Retinal) by night, providing a simple, evidence-based routine designed to address up to 90% of visible skin aging concerns.

Medik8 will debut on Sephora.com in the United States on August 11, with its rollout across 250 four-shelf Sephora gondolas in U.S. stores, offering a full expression of the Medik8 brand, completed by August 21, alongside availability in 147 Sephora locations across Canada. 

In Canada, the brand will achieve full distribution across all 147 Sephora locations, including dedicated Medik8 gondolas in 75 stores for additional brand visibility.

The expansion follows L’Oréal Groupe’s acquisition of a majority stake in Medik8 in 2025, providing the brand with additional resources and bringing Medik8’s clinically proven products into the hands of more consumers.